Needham Maintains Buy on Stoke Therapeutics, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 80.9%

Neg 0% Neu 0% Pos 80.9%

Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $35 to $40.